All News
Stopping therapy in GCA
They say the easiest bit about GCA, like PMR, is the first week after you start steroids. Those fond memories belie the challenge of ongoing treatment in GCA. In a steroid-only world, there is only misery. Steroid-sparing therapies have changed this completely.
Read Article
Weight Loss as a Therapeutic Goal in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.
Read Article
#ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity in #Sjogren Disease presented during Late Breaking Abstract session Abstr#LB24 #SjD @RheumNow
https://t.co/ngCAglwAO0 https://t.co/PaUYsxhBKS
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In the epidemiology session on the final day of #ACR25, a large cohort study (>430k pts) showed that GLP-1 receptor agonists were linked to lower incidence of RA, gout & OA vs DPP-4 inhibitors. Adds to the growing case for GLP-1 benefits beyond glucose control. @RheumNow #2657
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow!
GC #steroid burden & Mx
Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d
Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic
@RheumNow https://t.co/paw7NGjs4p
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What exercise best for steroid-induced osteoporosis? Does it have to be weight bearing?
Turns out anything helps - get out there and don’t let perfect be the enemy of good!
Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/VGH2rz3dzb
David Liew drdavidliew ( View Tweet)
Trends in Translational Abstracts content this year by Tomas Mustelin in the
“Abstracts that Will shape research in the near Future” Year in Preview session
@RheumNow #ACR25 https://t.co/i5CA8cxHeQ
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Clinical Preview by Prof Coates to be applied tomorrow!
Early Tx
Abstr#1677 First-line TNFi for 12-mth vs step-up = better outcomes at 5-Yr
Abstr#2662 Target emulation trial = No differences in hospitalization, death/transplant RTX vs TNFi, ABA, JAK, IL-6i @RheumNow https://t.co/yostJyc5T9
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
@Yuz6Yusof gets a shout out from Laura Coates in the #ACR25 meeting review for his work on rituximab super-responders in SLE
@RheumNow https://t.co/EKUgmENesX
Links:
David Liew drdavidliew ( View Tweet)
Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels.
Yet drug concentrations and TDM are not commonplace in many places - time for change
Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc
David Liew drdavidliew ( View Tweet)
Year in Preview
GCA: GC over-prescribed, bDMARDs more effective than MTX, and more options available (TOC, JAKi)
@RheumNow #ACR25 https://t.co/L9fx1LCCnw
Links:
Jiha Lee JihaRheum ( View Tweet)
“We’ve got to do better for our patients with GCA” - Laura Coates, doing the #ACR25 meeting review
She told us she is speaking about diseases outside her comfort zone but she is bang on.
As she said: not good enough real world all the people not on steroid-sparing Rx
@RheumNow https://t.co/4WiEORwPgI
David Liew drdavidliew ( View Tweet)
#YearInPreview at #ACR25
@DrLauraCoates introduces the session with a teaser for work that will be presented later today.
Are we entering an era in which we will be able to prevent #PsA?
Find out more at 12:00 today, Abs #2689
@RheumNow https://t.co/GDTBGNTCCd
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Rheum Now Rheumatology Round-Up — LIVE
Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25.
📡 Live https://t.co/GXxmtoluBc
Dr. John Cush RheumNow ( View Tweet)
Dr. LRoss presents the SCTC SSc Heart Involvement classification criteria
♥️Criteria score >/= 11pts
🔸SN 77.8%; SP 95.9%
🔸OR 82.6
Huge endeavor towards standardization of SHI to help improve patient outcomes in the future 👏👏
#ACR25 @RheumNow https://t.co/QrgYlksjZB
Links:
sheila RHEUMarampa ( View Tweet)
#ACR25 Abstr#LB24 The first Phase 3 RCTs in #Sjogren meeting primary endpoint! In moderate-to-severe activity, both RCTs = improvement in ESSDAI vs PBO (pooled effect -1.2 reduction). High PBO rate. PGA, PaGA & Stimulated Salivary Flow) improved. No diff in ESSPRI/FACIT @RheumNow https://t.co/rAs6NeXDIn
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI. Big placebo effect also. Patient and physician global also improved. @RheumNow #ACR25 Abstr#LB24 https://t.co/klhxXW4Jfh
Richard Conway RichardPAConway ( View Tweet)
Useful clinical pearls by @Janetbirdope on ANA testing @RheumNow #ACR25 #ACRBest https://t.co/1FMv5nIWNe
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Questions #ACR25 LB20 to Paul Emery on rosnilimab:
Fleischmann: could be induction therapy? (Not intent, but could be)
Choy: Depth of changes with translational data
Tanaka: Safety given peresolimab ph2b here (diff epitope, membrane proximity, targeted depletion PD-1hi)
@RheumNow
David Liew drdavidliew ( View Tweet)
